Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study
| Autor: | Itamar Raz, Gil Leibowitz, Benjamin M. Scirica, Cheryl Wei, W. H.-H. Sheu, Eugene Braunwald, J. L. Sendon, Avivit Cahn, Deepak L. Bhatt, Ofri Mosenzon, Boaz Hirshberg, György Jermendy, KyungAh Im |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Adamantane Type 2 diabetes Dipeptidyl peptidase-4 inhibitor Pharmacology Saxagliptin Placebo Gastroenterology chemistry.chemical_compound Endocrinology Double-Blind Method Insulin-Secreting Cells Internal medicine Diabetes mellitus Internal Medicine Humans Hypoglycemic Agents Insulin Medicine Prospective Studies Aged Glycated Hemoglobin Dipeptidyl-Peptidase IV Inhibitors business.industry Hazard ratio Dipeptides Fasting Middle Aged medicine.disease Diabetes Mellitus Type 2 chemistry Female business TIMI medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 17:487-494 |
| ISSN: | 1462-8902 |
| DOI: | 10.1111/dom.12445 |
| Popis: | Aims To study the effects of saxagliptin, a dipeptidyl peptidase-4 inhibitor, on glycaemic stability and β-cell function in the SAVOR-TIMI 53 trial. Methods We randomized 16 492 patients with type 2 diabetes (T2D) to saxagliptin or placebo, added to current antidiabetic medications, and followed them for a median of 2.1 years. Glycaemic instability was defined by: (i) a glycated haemoglobin (HbA1c) increase of ≥0.5% post-randomization; (ii) the initiation of new antidiabetic medications for ≥3 months; or (iii) an increase in dose of oral antidiabetic medication or ≥25% increase in insulin dose for ≥3 months. β-cell function was assessed according to fasting homeostatic model 2 assessment of β-cell function (HOMA-2β) values at baseline and at year 2 in patients not treated with insulin. Results Compared with placebo, participants treated with saxagliptin had a reduction in the development of glycaemic instability (hazard ratio 0.71; 95% confidence interval 0.68–0.74; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text